Clinical Trial Update: A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the duration of action of PF-03526299 in asthmatic subjects following an allergen challenge has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• PF-03526299

Snippet

Sponsor: Pfizer | Conditions: Asthma | Phase 1 | Status: WITHDRAWN